Fairvalue-Calculator Fairvalue-Calculator
EN DE

Acarix AB (ACARIX) Fair Value & Analysis

Healthcare · SE · Market cap 306M SEK

Pricekr 0.2650
Fair Valuekr 0.1400
Upside-47.2%
Quality95/100
Evidence: Low Range kr 0.1100 – kr 0.1800

Fair value as of: Jun 24, 2026

Analysis

Acarix AB (ACARIX) currently trades at kr 0.2650, while our model-based Fair Value estimate is kr 0.1400 — implying the stock looks roughly 47.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Acarix AB (ACARIX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 0.1400 versus a price of kr 0.2650 — about −47% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ACARIX?
Our 21-model fair value for Acarix AB is kr 0.1400 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 0.2650.
What is the quality score of ACARIX?
Acarix AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.